Accurate Wealth Management LLC decreased its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,653 shares of the company’s stock after selling 2,133 shares during the period. Accurate Wealth Management LLC’s holdings in Cencora were worth $2,233,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of COR. IAG Wealth Partners LLC purchased a new stake in shares of Cencora in the 3rd quarter valued at about $30,000. Cloud Capital Management LLC bought a new stake in shares of Cencora during the third quarter valued at approximately $31,000. Caitlin John LLC bought a new position in shares of Cencora in the third quarter worth about $31,000. Westside Investment Management Inc. lifted its holdings in Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after purchasing an additional 70 shares in the last quarter. Finally, Harbor Investment Advisory LLC purchased a new stake in shares of Cencora during the 4th quarter valued at about $35,000. Institutional investors own 97.52% of the company’s stock.
Insider Buying and Selling at Cencora
In related news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on COR
Cencora Stock Down 1.8%
COR stock opened at $312.28 on Friday. Cencora, Inc. has a one year low of $267.40 and a one year high of $377.54. The firm has a market cap of $60.75 billion, a PE ratio of 37.53, a PEG ratio of 1.48 and a beta of 0.68. The firm’s 50 day moving average price is $352.05 and its 200-day moving average price is $340.52. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.
Cencora (NYSE:COR – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.73 earnings per share. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is currently 28.85%.
About Cencora
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
See Also
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
